Ebumab Sandbox ApS: Financial statements 2024
CVR: 43575627
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Ebumab Sandbox ApS (CVR 43575627) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -10,000 and a net result of DKK -7,800. Equity in the 2024 report amounted to DKK 26,342. The solvency ratio was 100%.
- Gross Profit
- DKK -10,000
- Profit/Loss
- DKK -7,800
- Equity
- DKK 26,342
- Total Assets
- DKK 26,342
- Employees
- 0
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Ebumab Sandbox ApS has published its interim report for the period October 12, 2022 to December 31, 2023.
About Ebumab Sandbox ApS
Ebumab Sandbox ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hans Heugh Wandall and Johan Henrik Faber. The board consists of Thomas Dal Stenfeldt Batchelor (chair), Hans Heugh Wandall, Johan Henrik Faber and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -12,630 and a net result of DKK -11,150 compared with DKK -7,800 the year before. Equity in the 2025 report amounted to DKK 15,192.